Dupilumab for treatment of eosinophilic fasciitis.
RuiYuan XiaJian LiuTing SuJiPing XiaZhiqiang YinPublished in: Clinical and experimental dermatology (2022)
This is the first report, to our knowledge, of the use of dupilumab in treating eosinophilic fasciitis (EF). Our case supports that Type 2 innate immunity might be related to EF and that T helper 2 cytokines play important roles in EF.